Clinical Trials Browser

Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05826535 2026-02-24

Study of LYL314 in Aggressive Large B-Cell Lymphoma

Immune System Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Disease Attributes

NCT02625480 2025-09-29

ZUMA-4

Phase 1/2 Active not recruiting

95 enrolled

Lymphoid

Recurrence, Lymphoma, B-Cell

NCT04697940 2025-09-19

Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL

Phase 1/2 Active not recruiting

33 enrolled

Lymphoid

Recurrence, Lymphoma, B-Cell

NCT06838832 2025-07-30

Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL

Phase 1/2 Recruiting

30 enrolled

Recurrence

NCT06834529 2025-02-19

CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma

Phase 1/2 Recruiting

20 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Recurrence, Leukemia, B-Cell, Lymphoma, B-Cell

NCT03658785 2024-08-13

Immunotherapy for the Treatment of Advanced Solid Tumor

Phase 1/2 Recruiting

40 enrolled

Neoplasm Metastasis, Recurrence

NCT03056339 2024-03-25

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

Phase 1/2 Completed

49 enrolled 12 charts

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04030195 2023-01-31

Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL

Phase 1/2 Completed

18 enrolled 13 charts

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT01289457 2020-02-24

Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome

Phase 1/2 Completed

282 enrolled 13 charts

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT03916679 2019-04-16

MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer

Phase 1/2 Unknown

20 enrolled

Gynecologic

Ovarian Neoplasms, Recurrence

NCT01322776 2011-03-25

Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma

Phase 1/2 Unknown

40 enrolled

Lymphoid

Recurrence, Lymphoma, Mantle-Cell

Clinical Trials

ALPHA2

Study of LYL314 in Aggressive Large B-Cell Lymphoma

ZUMA-4

Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL

Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL

CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma

Immunotherapy for the Treatment of Advanced Solid Tumor

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL

Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome

MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer

Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma